Single-institution experience with gemcitabine–cisplatin combination therapy as a second-line treatment for patients with unresectable biliary tract cancer after failure of gemcitabine–S-1 combination therapy: a prospective feasibility study

被引：0
作者：
Ryusei Matsuyama
Daisuke Morioka
Ryutaro Mori
Seigo Hiratani
Yasuhiro Yabushita
Yohei Ota
Takafumi Kumamoto
Koichi Taniguchi
Itaru Endo
机构：
[1] Yokohama City University Graduate School of Medicine,Department of Gastroenterological Surgery
来源：
Cancer Chemotherapy and Pharmacology | 2018年 / 81卷
关键词：
Biliary tract cancer; Gemcitabine; Cisplatin; S-1; Refractory;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：949 / 955
页数：6
相关论文
共 76 条
[1]  
Gores GJ(2003)Cholangiocarcinoma: current concepts and insight Hepatology 37 961-969
[2]  
Rajagopalan V(2004)Gallbladder and biliary tract carcinoma: a comprehensive up date, Part 1 Oncology 18 889-896
[3]  
Daines WP(2007)International comparisons of cumulative risk of gallbladder cancer and other biliary tract cancer, from cancer incidence in five continents Jpn J Clin Oncol 37 74-75
[4]  
Grossbard ML(2009)Epidemiology of biliary tract cancers: an update Ann Oncol 20 146-159
[5]  
Matsuda T(2005)Biliary tract cancer: current concepts and controversies Expert Opin Pharmacother 6 211-223
[6]  
Marugame T(2007)Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials Br J Cancer 96 896-902
[7]  
Randi G(2010)Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer N Eng J Med 362 1273-1281
[8]  
Malvezzi M(2010)Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicenter study in japan Br J Cancer 103 469-474
[9]  
Levi F(2008)S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study Cancer Chemother Pharmacol 62 849-855
[10]  
Leonard GD(2010)Multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer Cancer Chemother Pharmacol 65 1101-1107
12345678